Table 1. . Association of clinical and pathological features with neutrophil percentage-to-albumin ratio in 213 patients treated with radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer.
| All cohort | NPAR <18 | NPAR ≥18 | p-value | |
|---|---|---|---|---|
| Total, n (%) | 213 | 152 (71.4) | 61 (28.6) | |
| Mean age, years (SD) | 65.86 (10) | 64.55 (8.9) | 69.13 (12) | 0.004 |
| Gender, n (%) | ||||
| Males | 176 (82.6) | 126 (82.9) | 50 (82) | 0.87 |
| Females | 37 (17.4) | 26 (17.1) | 11 (18) | |
| ASA score, n (%) | ||||
| 1 | 6 (2.8) | 4 (2.6) | 2 (3.3) | 0.69 |
| 2 | 99 (46.5) | 67 (44.1) | 32 (52.4) | |
| 3 | 101 (47.4) | 76 (50) | 25 (41) | |
| 4 | 7 (3.3) | 5 (3.3) | 2 (3.3) | |
| ECOG score, n (%) | ||||
| 0 | 121 (56.8) | 88 (57.9) | 33 (54.1) | 0.14 |
| 1 | 69 (32.3) | 52 (34.2) | 17 (27.9) | |
| 2 | 13 (6.1) | 8 (5.2) | 5 (8.2) | |
| 3 | 4 (2) | 1 (0.7) | 3 (4.9) | |
| 4 | 6 (2.8) | 3 (2) | 3 (4.9) | |
| Preoperative hydronephrosis, n (%) | ||||
| No | 165 (77.5) | 121 (79.6) | 44 (72.1) | 0.23 |
| Yes | 48 (22.5) | 31 (20.4) | 17 (27.9) | |
| Hemoglobin mean (SD) | 12.61 (1.96) | 12.54 (2) | 12.78 (1.8) | 0.19 |
| Creatinine mean (SD) | 1.17 (0.64) | 1.24 (0.72) | 1.01 (0.29) | 0.001 |
| BMI mean (SD) | 25.92 (3.68) | 26.57 (3.67) | 24.29 (3.18) | 0.001 |
| Cholesterol mean (SD) | 202 (38.17) | 198.2 (36.96) | 211.5 (39.79) | 0.02 |
| Fibrinogen mean (SD) | 3.1 (1.2) | 2.93 (1.19) | 3.53 (1.17) | 0.01 |
| NLR mean (SD) | 2.77 (1.68) | 2.1 (1.03) | 4.43 (1.83) | <0.001 |
| NAC cycles, n (%) | ||||
| =3 | 148 (69.5) | 112 (73.7) | 36 (59) | 0.051 |
| >3 | 65 (30.5) | 40 (26.3) | 25 (41) | |
| Clinical stage at RC, n (%) | ||||
| CIS | 4 (1.9) | 4 (2.6) | 0 (0) | 0.03 |
| T1 | 27 (12.7) | 21 (13.8) | 6 (9.8) | |
| T2 | 99 (46.4) | 63 (41.5) | 36 (59) | |
| T3 | 56 (26.3) | 47 (30.9) | 7 (14.8) | |
| T4 | 27 (12.7) | 17 (11.2) | 10 (16.4) | |
| Histology, n (%) | ||||
| Pure UC | 184 (86.4) | 129 (84.9) | 55 (90.2) | 0.3 |
| Nonpure UC | 29 (13.6) | 23 (15.1) | 6 (9.8) | |
| Node status at RC, n (%) | ||||
| N0 | 193 (90.6) | 142 (93.4) | 51 (83.6) | 0.07 |
| N1 | 13 (6.3) | 6 (4) | 7 (11.5) | |
| N2 | 7 (3.3) | 4 (2.6) | 3 (4.9) | |
| Metastasis status at RC, n (%) | 0.79 | |||
| No | 207 (97.2) | 148 (97.4) | 59 (96.7) | |
| Yes | 6 (2.8) | 4 (2.6) | 2 (3.3) | |
| Lymphadenectomy extension | ||||
| Standard | 171 (80.3) | 122 (80.3) | 49 (80.3) | 0.99 |
| Extended | 42 (19.7) | 30 (19.7) | 12 (19.7) | |
| Nodes removed | 18.21 (9.35) | 19.6 (9.1) | 14.77 (9.14) | 0.0007 |
| Positive nodes | 1.2 (3.34) | 1.32 (3.86) | 0.91 (1.34) | 0.25 |
| Pathological stage, n (%) | ||||
| T0 | 47 (22.1) | 38 (25) | 9 (14.8) | 0.33 |
| Tis | 13 (6.1) | 9 (5.9) | 4 (6.5) | |
| Ta | 9 (4.2) | 4 (2.6) | 5 (8.2) | |
| T1 | 18 (8.5) | 13 (8.5) | 5 (8.2) | |
| T2 | 42 (19.7) | 32 (21.1) | 10 (16.4) | |
| T3 | 58 (27.2) | 38 (25) | 20 (32.8) | |
| T4 | 26 (12.2) | 18 (11.9) | 8 (13.1) | |
| Node status after RC, n (%) | ||||
| N0 | 183 (85.9) | 132 (86.8) | 51 (83.6) | 0.11 |
| N1 | 9 (4.2) | 8 (5.3) | 1 (1.7) | |
| N2 | 17 (7.9) | 11 (7.3) | 6 (9.8) | |
| N3 | 4 (2) | 1 (0.6) | 3 (4.9) | |
| Adjuvant treatment, n (%) | ||||
| No | 191 (89.7) | 135 (88.8) | 56 (91.8) | 0.64 |
| Chemotherapy | 12 (5.6) | 10 (6.6) | 2 (3.3) | |
| Radiotherapy | 10 (4.7) | 7 (4.6) | 3 (4.9) |
Boldface values represent statistically significant p < 0.05.
ASA: American society of Anesthesiologists; CIS: Carcinoma in situ; ECOG: Eastern cooperative oncology group; NAC: Neoadjuvant chemotherapy; NLR: Neutrophil-to-lymphocyte ratio; NPAR: Neutrophil percentage-to-albumin ratio; RC: Radical cystectomy; SD: Standard deviation; UC: Urothelial cancer.